In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a "master regulator" ...

Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $131 from $128 and keeps an Overweight ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Corcept Therapeutics Incorporated’s CORT share price has dipped by 19.51%, which has investors questioning if this is right time to buy.

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Learn more about whether Corcept Therapeutics Incorporated or Zoetis Inc. is a better investment based on AAII's A+ Investor ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT. And retail traders should ...

Menlo Park-based Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...